Thermo Fisher Scientific is expanding its oral solid dose (OSD) development and manufacturing capabilities across North America with a $22 mn investment in its Cincinnati, Ohio, and Bend, Oregon sites. The expansion enhances R&D, manufacturing, and testing capabilities to support early drug development and accelerate clinical timelines, and the upgrades include new facilities for advanced drug delivery and formulation technologies, addressing challenges in solubility and bioavailability.

Ask any executive why they think there are drug shortages, and they will no doubt blame some combination of the long-lasting impact of the global pandemic, inflation, energy costs and global conflicts.

A significant rise in biotech stocks has been partly attributed to escalating fears over avian influenza and the ongoing development of related vaccines.

To respond to a greater proportion of clients’ projects requiring potent drug capabilities, specialist oral dose CDMO Adare is to extend its high potency handling and packaging capabilities in Philadelphia, Vandalia in Ohio, and Milan, Italy.

At the CPHI Pharma Awards, CDMO Catalent scooped first place in the Supply Chain Excellence category. The company’s case management services provide professional end-to-end supply chain management and orchestration for autologous and allogeneic cell and gene therapies, and is designed to address the unique challenges associated with the safe and timely delivery of ATMPs.